Vitrolife completes a directed share issue of 9.6 million shares, raising proceeds of approximately SEK 3.6 billion
Vitrolife AB (publ) (“Vitrolife”) has, based on the authorisation granted by the annual general meeting on 28 April 2021 and in accordance with what Vitrolife indicated in a press release on 8 July 2021, resolved to carry out a directed share issue of 9,645,303 shares at a subscription price of SEK 368.92 per share. The subscription price has been determined through an accelerated book building procedure.Vitrolife announced yesterday the signing of the acquisition of Igenomix S.L.[1] (“Igenomix”) and Vitrolife intends to partly finance this acquisition with the proceeds from the directed